This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Armata Pharmaceuticals (ARMP) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Armata Pharmaceuticals (ARMP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Hyperfine, Inc. (HYPR) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Hyperfine (HYPR) delivered earnings and revenue surprises of 0% and 15.45%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Y-mAbs Therapeutics, Inc. (YMAB) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Y-mAbs Therapeutics, Inc. (YMAB) delivered earnings and revenue surprises of -12.50% and 0.53%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Armata Pharma (ARMP) Stock Surges 130% in a Month: Here's Why
by Zacks Equity Research
Armata Pharma (ARMP) stock skyrockets 130% in a month due to encouraging progress of the company's pathogen-targeting natural and synthetic phage candidates.
Armata Pharmaceuticals, Inc. (ARMP) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
Cardiff Oncology (CRDF) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Cardiff Oncology (CRDF) delivered earnings and revenue surprises of 7.41% and 44%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Ligand Pharmaceuticals (LGND) Q2 Earnings Beat Estimates
by Zacks Equity Research
Ligand (LGND) delivered earnings and revenue surprises of 86.84% and 5.85%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Morphic Holding, Inc. (MORF) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Morphic Holding, Inc. (MORF) delivered earnings and revenue surprises of -2.22% and 100%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Vericel Corporation (VCEL) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Vericel Corporation (VCEL) delivered earnings and revenue surprises of 15.38% and 7.27%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Armata Pharmaceuticals, Inc. (ARMP) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Armata Pharmaceuticals, Inc. (ARMP) delivered earnings and revenue surprises of -37.93% and 46.93%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Inovio Pharmaceuticals (INO) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Inovio (INO) delivered earnings and revenue surprises of -14.29% and 42.50%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Cue Biopharma, Inc. (CUE) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Cue Biopharma, Inc. (CUE) delivered earnings and revenue surprises of 12.12% and 37.67%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Armata Pharmaceuticals, Inc. (ARMP) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
by Zacks Equity Research
Armata Pharmaceuticals, Inc. (ARMP) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
After Plunging 35.3% in 4 Weeks, Here's Why the Trend Might Reverse for Armata Pharmaceuticals, Inc. (ARMP)
by Zacks Equity Research
Armata Pharmaceuticals, Inc. (ARMP) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Here's Why Armata Pharmaceuticals, Inc. (ARMP) Looks Ripe for Bottom Fishing
by Zacks Equity Research
Armata Pharmaceuticals, Inc. (ARMP) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Armata Pharmaceuticals, Inc. (ARMP) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Armata Pharmaceuticals, Inc. (ARMP) delivered earnings and revenue surprises of 11.11% and 3.04%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Calyxt (CLXT) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Calyxt (CLXT) delivered earnings and revenue surprises of 13.33% and 86%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Armata Pharmaceuticals, Inc. (ARMP) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Armata Pharmaceuticals, Inc. (ARMP) delivered earnings and revenue surprises of 0% and 98.21%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
TELA Bio, Inc. (TELA) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
TELA Bio, Inc. (TELA) delivered earnings and revenue surprises of -33.33% and 1.52%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Avidity Biosciences, Inc. (RNA) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Avidity Biosciences, Inc. (RNA) delivered earnings and revenue surprises of -24.32% and 4.77%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Armata Pharmaceuticals, Inc. (ARMP) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Armata Pharmaceuticals, Inc. (ARMP) delivered earnings and revenue surprises of -50% and 30.11%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
TFF Pharmaceuticals, Inc. (TFFP) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
TFF Pharmaceuticals, Inc. (TFFP) delivered earnings and revenue surprises of 13.16% and 33%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Myovant Sciences (MYOV) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Myovant Sciences (MYOV) delivered earnings and revenue surprises of -14.55% and 5.26%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Wall Street Analysts See a 52% Upside in Armata Pharmaceuticals, Inc. (ARMP): Can the Stock Really Move This High?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 52.5% in Armata Pharmaceuticals, Inc. (ARMP). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Recent Price Trend in Armata Pharmaceuticals, Inc. (ARMP) is Your Friend, Here's Why
by Zacks Equity Research
Armata Pharmaceuticals, Inc. (ARMP) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.